A 52-year-old woman from Mumbai presents with involuntary choreiform movements of the limbs, emotional lability, and cognitive decline over 18 months. Family history reveals her father died of a similar illness at age 55. Genetic testing confirms CAG trinucleotide repeat expansion in the huntingtin gene. Which investigation is most appropriate to assess the structural and functional integrity of the basal ganglia circuits and correlate with disease severity?

Explanation

## Investigation of Choice for Huntington's Disease: Assessing Basal Ganglia Pathology ### Clinical Context The patient presents with the classic triad of Huntington's disease (HD): chorea, cognitive decline, and psychiatric symptoms, confirmed by genetic testing showing CAG repeat expansion. Assessment of structural basal ganglia changes is crucial for staging disease severity and predicting progression. ### Why Volumetric MRI is the Answer **Key Point:** Volumetric MRI measuring striatal (particularly caudate and putamen) volume loss is the most established, clinically practical, and prognostically relevant structural neuroimaging biomarker in Huntington's disease. **High-Yield:** In HD, selective neuronal loss in the striatum (caudate > putamen) occurs early and correlates strongly with: - Disease duration - Motor symptom severity (chorea burden) - Cognitive decline - CAG repeat length (longer repeats → earlier onset and faster progression) - Functional disability Striatal atrophy is detectable on conventional MRI and can be quantified volumetrically, making it a practical biomarker for disease staging and monitoring therapeutic response. **Clinical Pearl:** In Indian clinical practice, volumetric MRI is: - Widely available - Non-invasive and repeatable - Cost-effective - Used to stage disease severity (early, intermediate, advanced based on degree of striatal atrophy) - Useful for family screening in at-risk relatives ### Pathophysiology of Striatal Degeneration in HD The mutant huntingtin protein causes selective vulnerability of medium spiny neurons (MSNs) in the striatum, particularly those expressing D2 dopamine receptors (indirect pathway neurons). This leads to: 1. Early loss of indirect pathway function → disinhibition of thalamus → hyperkinetic movement disorder (chorea) 2. Progressive loss of both direct and indirect pathway neurons → bradykinesia and rigidity (late disease) 3. Volumetric atrophy visible on MRI correlates with this neuronal loss ### Comparison of Neuroimaging Modalities in HD | Investigation | Detects | Clinical Use | Correlation with Severity | |---|---|---|---| | **Volumetric MRI** | **Structural striatal atrophy** | **Disease staging, prognosis, monitoring** | **Strong (striatal volume ↓ with CAG repeats and disease duration)** | | fMRI | Altered BOLD activation during tasks | Research, mechanism studies | Moderate (shows circuit dysfunction) | | DTI | White matter tract integrity | Research (corpus callosum, commissural tracts) | Weak-moderate | | PET (11C-raclopride) | D2 receptor availability | Research (dopaminergic dysfunction) | Moderate (receptor loss) | ### Why Volumetric MRI is Superior for Clinical Practice **Key Point:** Striatal volume loss in HD is: - **Objective and quantifiable** — allows precise measurement and longitudinal tracking - **Prognostically relevant** — predicts rate of symptom progression and functional decline - **Widely available** — no special equipment or radiotracers needed - **Clinically actionable** — guides therapeutic decisions and family counseling - **Correlates with pathology** — reflects underlying neuronal loss in the striatum ### Why Other Options Are Suboptimal for This Question - **fMRI:** Detects altered activation patterns during motor tasks but is primarily a research tool. While it shows circuit dysfunction, it does not directly quantify structural pathology or provide prognostic information as reliably as volumetric MRI. - **DTI:** Assesses white matter integrity (corpus callosum, commissural tracts are affected in HD) but is less clinically practical and does not correlate as strongly with motor severity as striatal volume does. - **PET with 11C-raclopride:** Measures D2 dopamine receptor availability and shows reduced binding in the striatum (reflecting neuronal loss and dopaminergic dysfunction). While informative, it is: - Expensive and requires a cyclotron - Not widely available in India - Primarily a research tool - Does not provide better prognostic information than volumetric MRI ### Clinical Application: Disease Staging by Striatal Volume ```mermaid flowchart TD A[Huntington's Disease Diagnosis Confirmed]:::outcome --> B[Volumetric MRI of Basal Ganglia]:::action B --> C{Striatal Volume}:::decision C -->|Normal-mild atrophy| D[Early Stage Disease]:::outcome C -->|Moderate atrophy| E[Intermediate Stage Disease]:::outcome C -->|Severe atrophy| F[Advanced Stage Disease]:::outcome D --> G[Genetic counseling, family screening]:::action E --> H[Symptom management, monitor progression]:::action F --> I[Intensive supportive care, advanced planning]:::action ``` ### Guideline Recommendation The Huntington's Disease Society of America and Movement Disorder Society recommend volumetric MRI as the standard structural neuroimaging biomarker for disease assessment, prognostication, and monitoring in HD [cite:HD Society Guidelines].